Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection

Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-spec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2002-01, Vol.185 (1), p.61-8
Hauptverfasser:	Dybul, Mark, Hidalgo, Bertha, Chun, Tae-Wook, Belson, Michael, Migueles, Stephen A., Justement, Jesse S., Herpin, Betsey, Perry, Cheryl, Hallahan, Claire W., Davey, Richard T., Metcalf, Julia A., Connors, Mark, Fauci, Anthony S.
Format:	Artikel
Sprache:	eng
Schlagworte:	AIDS Anti-HIV Agents - therapeutic use Antigens Antiretroviral Therapy, Highly Active B lymphocytes Benzoxazines Biological and medical sciences CD4 antigen CD4-Positive T-Lymphocytes - immunology CD8 antigen CD8-Positive T-Lymphocytes - immunology Coculture Techniques Drug Synergism Highly active antiretroviral therapy HIV HIV 1 HIV infections HIV Infections - drug therapy HIV Infections - immunology HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Human viral diseases Humans Indinavir - therapeutic use Infections Infectious diseases Interferon-gamma - biosynthesis Interleukin-2 - administration & dosage Interleukin-2 - therapeutic use Lamivudine - therapeutic use Lymphocyte Activation Lymphocyte Subsets Major Articles Medical sciences Oxazines - therapeutic use Pilot Projects Reverse Transcriptase Inhibitors - therapeutic use Stavudine - therapeutic use T lymphocytes Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-specific immune responses are augmented by the administration of the immunomodulatory agent interleukin (IL)–2. Nine persons recently (
ISSN:	0022-1899 1537-6613
DOI:	10.1086/338123